Saji S, Taira N, Kitada M, Takano T, et al. Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. Lancet Oncol 2022 Apr 8. pii: S1470-2045(22)00196.
PMID: 35405087